About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, May 17th, 2017

The QualityStocks
Daily Stock List


Manhattan Scientifics, Inc. (MHTX)

SmallCapVoice, OurHotStockPicks, Hawk Associates, AllPennyStocks, Xtremepicks, FeedBlitz, StockHotTips, The Penny Play, BullRally, and HotStockChat reported on Manhattan Scientifics, Inc. (MHTX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Manhattan Scientifics, Inc. centers on the commercialization of disruptive technologies in the nano-medicine space. At present, it is developing commercial medical prosthetics applications for its ultra-fine grain metals. The Company’s goal is to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, (now Imagion Biosystems) its wholly-owned subsidiary. Manhattan Scientifics has its corporate office in New York, New York and an office in Albuquerque, New Mexico (Imagion Biosystems).

The Company has expertise in licensing from the national laboratories (the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL)) and in working with individual inventors. Its technology employs iron oxide nanoparticles and a technique it calls Magnetic Relaxometry to locate and measure cancers with a sensitivity that would provide a diagnosis years before other known methods.

In essence, Manhattan Scientifics focuses on technology transfer and commercialization of transformative technologies in the nano medicine space. It creates Intellectual Property (IP) portfolios and business cases supporting new technologies. The Company guides them to relationships with industrial partners who are well-prepared to launch product. As a result, the lab and inventor see the technology enter the market. The industrial partner gets a strong foundation for a new product. Manhattan Scientifics profits from building the licensing bridge to industry.
Manhattan Scientifics is now concentrating on nanostructured metals technology via wholly-owned subsidiary Metallicum, Inc.  In addition, it is centering on nanoparticle based cancer detection through Senior Scientific.

Furthermore, it is working on the start of product trials on its cancer detection product. The nanostructured metals technology has been revenue producing for some years. The cancer detection technology can detect cancer years earlier.

Manhattan Scientifics has an agreement to collaborate with The University of Texas M.D. Anderson Cancer Center (MDACC) to advance, demonstrate, and validate a ground-breaking technology developed by Mr. Edward R. Flynn, PhD, for the very early detection of cancer. Manhattan Scientifics has delivered its innovative cancer measurement instrument to MDACC.

Senior Scientific has established a research collaboration with Weill Cornell Medicine. For this alliance, it will bring its magnetic relaxometry technology to Weill Cornell Medicine. Scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate cancers.

This past February, Manhattan Scientifics announced the retirement of $2.5 million in current debt. It said it now has a virtually debt-free balance sheet. The $2.5 million debt was owed by the Company’s subsidiary, Senior Scientific, now Imagion Biosystems. Manhattan Scientifics reported the debt on its balance sheet as it is the sole owner of Senior Scientific.

As part of the spin-off of Senior Scientifics, Imagion Biosystems was required to retire the debt. With the $2.0M debt repayment, and with the lender's conversion to equity of the remaining $500,000, the $2.5M debt is no longer an obligation of Manhattan Scientifics.

Manhattan Scientifics, Inc. (MHTX), closed Wednesday's trading session at $0.02575, up 0.19%, on 20,500 volume with 7 trades. The average volume for the last 60 days is 190,068 and the stock's 52-week low/high is $0.018/$0.076.

International Western Petroleum, Inc. (INWP)

Equities, Stock News Now, and DreamTeamNetwork reported on International Western Petroleum, Inc. (INWP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Western Petroleum, Inc. is an E&P (Exploration & Production) company headquartered in Irving, Texas. It specializes in the acquisition, development, and exploration of crude oil and natural gas properties in Texas. The Company is working to acquire oil and gas properties. It is also working to apply the latest technologies and production techniques to increase acreage, productions, and reserves with an emphasis in the Central West Texas area. International Western Petroleum lists on the OTCQB.

International Western Petroleum will be centering on regional acquisition(s) with an emphasis in the Permian Basin region. The Company’s area of interest is production locations within the Wolfcamp shale in the Midland Basin section of the Texas Permian Basin.

The Company has acquired, from its operating partner International Western Oil Corp., working interests (WI’s) of two oil and gas production fields having proven reserves of roughly 154 Mbbl oil and 120 MMcf natural gas in Recoverable Net Reserves (PV10 report) in Coleman County, Texas.

International Western Oil secured a number of concessions encompassing approximately 2,400 acres in the Central West Texas region. Outside of the Central West Texas region and within the U.S., the Company has accessibility to around 95,000 acres of large-reserve oil and gas concessions, now under Company management review for acquisition efforts.

International Western Petroleum completed an acquisition, in September 2016, of a producing oil field in Kilgore, Texas, through the Marshall Walden Joint Venture (JV), a partnership with Odyssey Enterprises, LLC. International Western Petroleum is the managing venturer in this JV with Odyssey, which financed the JV for the lease purchase and optimization of wells situated in Kilgore, in the heart of the well-known Woodbine formation. There are 8 wellbores in the acquisition -  4 now in production and 4 inactive.

International Western Petroleum announced in November 2016 that it decided to work with a technology company providing a state-of-the-art Organic Oil Recovery (OOR) process. This process can release trapped oil without exploration risks. Additionally, International Western Petroleum commenced initial field works in its own productions. This is while exploring this new technology, starting with the East Texas and Central West Texas areas.

International Western Petroleum announced, in December 2016, that it acquired a 3D Seismic 350-acre leasehold in King County, Texas. The acquisition primarily includes a 350-acre leasehold in King County, Texas, with additional options to lease up to 800 acres of adjoining acreage with complete 3D seismic data.

International Western Petroleum has initiated a new acquisition model based on the financed acquisition of mature oil fields that have great potential for the application of an Advanced Enhanced Oil Recovery (EOR) process, and also based on strategic partnerships with existing operators to share production increases acquired via the implementation of this EOR process.

International Western Petroleum, Inc. (INWP), closed Wednesday's trading session at $0.29, up 7.41%, on 9,790 volume with 5 trades. The average volume for the last 60 days is 11,520 and the stock's 52-week low/high is $0.20/$1.80.

Foothills Exploration, Inc. (FTXP)

MarketWired, Bloomberg, OTC Markets, and ADVFN reported earlier on Foothills Exploration, Inc. (FTXP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Foothills Exploration, Inc., by way of its wholly-owned subsidiary Foothills Petroleum, Inc. (a Nevada corporation) is an early stage independent oil and gas exploration and production company. It engages in the acquisition and development of oil and gas properties in the Rockies and Gulf Coast. Foothills Exploration is based in Denver, Colorado and the Company lists on the OTCQB.

Foothill’s goal is to acquire dislocated and underdeveloped oil and gas assets and maximize those assets. The Company’s strategy is to build a balanced portfolio of E&P assets through focusing on acquiring producing and developmental properties in the Rockies and Gulf Coast regions, and centering on the generation of high-impact oil and gas exploration projects.

Foothills Exploration’s objective is to build a land bank of greater than 200,000 acres of proven, probable, and prospective reserves. At present, the Company holds 41,181 acres in the Greater Green River Basin in Wyoming. Its Springs Prospect comprises 38,120 contiguous acres. This is a multiple objective oil resource play in the Greater Green River Basin.

Additionally, the Company has a 35 percent Working Interest (WI) in the Ladysmith Anticline prospect. This prospect is in Fremont County, Wyoming. Ladysmith Anticline in entirety amounts to 3,061 acres. Its location is between the Great Divide/Greater Green River Basin and the Wind River Basin.

Foothills Exploration announced last December that it entered into a participation agreement with Magna Operating, LLC, concerning the Labokay prospect, covering 240 acres in Calcasieu Parish, Louisiana. Labokay is an amplitude versus offset (AVO) oil play in Southwestern Louisiana targeting the Frio Nododaria Blanpiedi Sand.

This agreement establishes an Area of Mutual Interest (AMI) between the parties for a five-year period. It provides Foothills Exploration with access to all of Magna Operating’s 3D seismic data. This includes interpretations and AVO data regarding the lands within the AMI.  Foothills Exploration will earn 100 percent WI before payout for drilling the well. Magna Operating will back in for a 20 percent WI after payout.

In February 2017, Foothills Exploration announced that since acquiring Tiger Energy Partners International on December 30, 2016, Foothills has successfully reworked two wells in its Duck Creek project obtaining production from the Green River formation.

Tempus Applied Solutions Holdings, Inc. (FTXP), closed Wednesday's trading session at $1.02, down 3.77%, on 6,800 volume with 18 trades. The average volume for the last 60 days is 11,933 and the stock's 52-week low/high is $1.00/$2.38.

AeroGrow International, Inc. (AERO)

StockOodles, Stockgoodies, Promotion Stock Secrets, Wall Street Mover, Marketbeat, SmallCapVoice, OTC Markets Group, StreetAuthority Daily, Greenbackers, Investor News Source, Stock Twiter, Damn Good Penny Picks, MyBestStockAlerts, Penny Stock Rumble, Penny Stocks Finder, Simply Best Penny Stocks, Stock Preacher, and TheLightningPicks reported earlier on AeroGrow International, Inc. (AERO), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

AeroGrow International, Inc. is the leader in the fast developing indoor gardening market. The Company’s AeroGardens enable anyone to grow fresh herbs, salad greens, tomatoes, chili peppers, flowers and more, indoors, all year. AeroGrow sells the Miracle-Gro AeroGarden® line of premier, soil-free indoor gardening systems.

AeroGrow International formed in July of 2002, and became a publicly-traded company on February 24, 2006. The Company has its corporate office in Boulder, Colorado. Its shares trade on the OTC Markets Group’s OTCQB.

In April of 2013, AeroGrow International entered into a strategic partnership with Scotts Miracle-Gro to continue to expand the indoor gardening market. All Miracle-Gro AeroGardens feature proprietary National Aeronautics and Space Administration (NASA) tested technology.

AeroGrow International is the manufacturer and distributor of the world's top indoor gardening systems - the AeroGarden line of Smart Countertop Gardens®. Miracle-Gro AeroGardens are complete indoor gardening systems with built in, full spectrum Grow Lights, patented hydroponic nutrients, and also user-friendly control panels, which automate important garden functions.

In addition, AeroGrow International develops, manufactures, and markets an array of consumable products for use in its gardens. These include Seed Kits, Grow Lights, hydroponic nutrients, and accessory products. The Company provides its products chiefly via retail distribution, catalogue, and direct-to-consumer sales channels.

In November 2016, AeroGrow International reported that the Scotts Miracle-Gro Company exercised its current outstanding warrants, establishing an 80 percent beneficial ownership position. The warrant exercise generates $47.8 million for AeroGrow, in exchange for 21.6 million shares in the Company to be issued to Scotts Miracle-Gro, bringing the total outstanding shares in AeroGrow International to roughly 33.9 million beneficial shares.

In February of this year, AeroGrow International announced results for Q3 ended December 31, 2016. Highlights include Q3 Sales being up 11 percent to $13.2 million. Year-to-date Sales were up 21 percent to $17.6 million. The Company had strong sales in on-line and retail channels, as well as high levels of sell-through.

AeroGrow International, Inc. (AERO), closed Wednesday's trading session at $2.52, down 0.40%, on 5,276 volume with 26 trades. The average volume for the last 60 days is 14,721 and the stock's 52-week low/high is $2.10/$5.85.

Petrolia Energy Corp. (BBLS)

MarketWatch and Market Exclusive reported on Petrolia Energy Corp. (BBLS), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Petrolia Energy Corp.’s main emphasis is using leading-edge technology and the implementation of its own pioneering, proprietary technologies to improve the recoverability of existing oil fields. The Company’s team of experts has a first-rate record of converting oil fields into compliant, producing, and profitable entities. Petrolia's main goals are to locate undervalued assets, identify properties with resolvable environmental and mechanical issues and lowering lift costs resulting in increased shareholder value.

OTCQB-listed, Petrolia Energy has its head office in Houston, Texas. The Company formerly went by the name Rockdale Resources Corp. A domestic oil exploration and production enterprise, Petrolia Energy concentrates on new oil wells in established areas of oil production. Petrolia Energy has more than 80 years of operational and management experience throughout the energy industry.

Petrolia Energy announced last October that it purchased a 90 percent working interest (WI) through a purchase and sale agreement (PSA) and a share exchange agreement (SEA) with Jovian Petroleum Corp. and its subsidiaries, Jovian Resources, LLC and SUDS Properties, LLC, increasing its ownership to 100 percent WI for the Slick Unit Dutcher Sands (SUDS) field in Creek County, Oklahoma. The combined value of the transaction was about $8.3 million.

This past December, Petrolia Energy announced that it earlier approved a multi-phase drilling program at its 100 percent owned Slick Unit Dutcher Sands Field (SUDS). Permits were filed and the first well, SUDS-PETROLIA #1, was scheduled to be drilled by the end of 2016. The Company anticipated drilling one additional producing well and one injection well by Q1 of 2017.

Earlier in 2017, Petrolia Energy completed the acquisition of 60 percent net working interest in the Twin Lakes San Andres Unit (TLSAU) lease, in Chaves County, New Mexico. This brings its total ownership of TLSAU to 100 percent.

On the whole, the TLSAU lease includes 4,864 gross and net acres; 2,292,903 barrels of 1P reserves; 44 existing vertical oil production wells, 12 that are presently producing; 44 existing injection wells for water flood and/or CO2 injection for enhanced oil recovery (EOR); wide-ranging surface infrastructure, including a 22-mile long water pipeline and a dedicated Caprock well to supply future water flood operations.

Petrolia Energy Corp. (BBLS), closed Wednesday's trading session at $0.135, down 0.74%, on 2,000 volume with 2 trades. The average volume for the last 60 days is 22,799 and the stock's 52-week low/high is $0.019/$0.1872.


The QualityStocks
Company Corner


Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0345, up 5.50%, on 1,983,787 volume with 145 trades. The stock’s average daily volume over the past 60 days is 5,559,944, and its 52-week low/high is $0.0062/$0.142.

SinglePoint, Inc., a holding company specialized in the acquisition of small to mid-sized companies with an emphasis on new technologies, today announces that it has signed an Letter of Intent ("LOI") with Discount Indoor Garden Supply ("DIGS"). According to the LOI, SinglePoint will acquire 90 percent of DIGS in a stock and cash transaction. The acquisition will bring immediate revenues to SinglePoint and positions the Company as a leader in online products, retail stores, cannabis consulting, and equipment in California, home to thousands of cannabis-related businesses and potential customers.

Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.

SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.

SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.

As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint Positioned to Secure Beachhead in California with Majority Stake in Cannabis Consulting, Equipment Company

SinglePoint, Inc. Gains Focus in NetworkNewsWire Publication Discussing How Innovators in the Diverse Marijuana Industry are Building Corporate Value

SinglePoint Signs Reseller Agreement for High Risk Merchant Processing

Stealth Technologies Inc. (STTH)

The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.0229, up 52.67%, on 6,560 volume with 1 trade. The stock’s average daily volume over the past 60 days is 32,445, and its 52-week low/high is $0.01/$0.05.

Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.

The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.

StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.

The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.

Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.

Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer

Stealth Technologies Inc. Company Blog

Stealth Technologies Inc. News:

Stealth Technologies Announces 5 New Products

Stealth Technologies Highlights Opportunities from Attendance at Leading Real Estate, Home Staging Conference

NetworkNewsWire Releases Exclusive Audio Interview with Stealth Technologies, Inc. (STTH)

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.15, up 8.77%, on 96,834 volume with 62 trades. The stock’s average daily volume over the past 60 days is 88,027, and its 52-week low/high is $0.1197/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

NetworkNewsWire Announces Publication on the Bullish Outlook for Zinc and the Companies Set to Profit

Kootenay Zinc Corp.: Sully Project Exploration Update

Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) is “One to Watch”

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.39, up 5.41%, on 94,970 volume with 291 trades. The stock’s average daily volume over the past 60 days is 397,068, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis-Based, Combination Therapies

IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain

IGC Sells Malaysian Hotel Investment Interest, Consolidates Corporate Focus on Development of Cannabis-Based Combination Therapies

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.443, up 0.68%, on 486,685 volume with 266 trades. The stock’s average daily volume over the past 60 days is 1,070,604, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(STTH) +52.67%


(NGTF) +34.42%


(ILUS) +27.91%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251